Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282230 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00282230 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 150 participants.
The verdict
NCT00282230, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
Interventions
- DRUG FK778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282230
The ClinicalTrials.gov registry entry for NCT00282230 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FK778 is the first listed.
NCT00282230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00282230 about?
NCT00282230 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients". A study to evaluate the safety and efficacy of Prograf/FK778 in de novo kidney transplant patients
What is the current status of trial NCT00282230?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-11. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00282230?
The interventions under investigation include: FK778 (DRUG).
Who is sponsoring clinical trial NCT00282230?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.